Overview

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Paliperidone Palmitate
Risperidone